definiens: means any CTLA-4 Variant that was discovered, invented, or reduced to practice ( i ) by, for, or on behalfof [COMPANY] or its Affiliates on or before the Effective Date, that has been identified by [COMPANY] as meeting the CompoundCriteria ( subject to Section 3.3.4 ), including those CTLA-4 Variants described on Exhibit 1.16 ( each, an ) or ( ii ) by, for, or on behalf of either Party or its Affiliates ( alone or jointly with others ) during the Term thatmeets the Compound Criteria . For clarity, except as conducted by, for, or on behalf of [COMPANY] prior to the Effective Date oras mutually agreed by the Parties in the Preclinical Development Plan, neither Party shall be required to screen or otherwisedetermine whether any specific CTLA-4 Variant meets the Compound Criteria